Clinical Trials at Hackensack University Medical Center

As of June 2026, 135 paid clinical trials are recruiting at Hackensack University Medical Center, located at 30 PROSPECT AVE, HACKENSACK, NJ 07601-1914, phone (201) 996-2210 in Hackensack, New Jersey. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

135 clinical trials at Hackensack University Medical Center

·Clear filters·↓ Download CSV

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

for Obstructive Hypertrophic Cardiomyopathy

Drug: Mavacamten

62 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05489705·Recruiting

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

165 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting

Apply to this trial

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

for Mucopolysaccharidosis II

8 locations incl. Oakland

Sponsor: Denali Therapeutics Inc.

Sex: All·Age: 2 - 25

Code: NCT05371613·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

for Malignant Glioma

Drug: Selinexor

109 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 Months - 21

Code: NCT05099003·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

for FSGS

54 locations incl. Birmingham

Sponsor: Dimerix Bioscience Pty Ltd

Sex: All·Age: 12 - 80

Code: NCT05183646·Phase 3·Recruiting

Apply to this trial

The CONFORM Pivotal Trial

for Atrial Fibrillation

76 locations incl. Birmingham

Sponsor: Conformal Medical, Inc

Sex: All·Age: 18+

Code: NCT05147792·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

for Lupus Nephritis

11 locations incl. Loma Linda

Sponsor: Hoffmann-La Roche

Sex: All·Age: 5 - 17

Code: NCT05039619·Phase 2·Recruiting

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

164 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting

Apply to this trial

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

219 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

227 locations incl. Alabaster

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting

Apply to this trial

Early Feasibility Study of the Cardiac Implants Percutaneous Ring Annuloplasty System

for Tricuspid Regurgitation Functional

2 locations incl. Hackensack

Sponsor: Cardiac Implants LLC

Sex: All·Age: 18+

Code: NCT04890821·Recruiting

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

258 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting

Apply to this trial

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

for Relapsed and/or Refractory B-cell Lymphoma

13 locations incl. Gilbert

Sponsor: Kite, A Gilead Company

Sex: All·Age: 18+

Code: NCT04989803·Phase 1, Phase 2·Recruiting

Apply to this trial

First in Human, Dose Escalation Study of AN4005

for Advanced Solid Tumor

4 locations incl. Hackensack

Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sex: All·Age: 18+

Code: NCT04999384·Phase 1·Recruiting

Apply to this trial

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

for Relapsed/Refractory Multiple Myeloma

Drug: Daratumumab

16 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT04973605·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

for Focal Segmental Glomerulosclerosis

Drug: Sparsentan

23 locations incl. Los Angeles

Sponsor: Travere Therapeutics, Inc.

Sex: All·Age: 1 - 17

Code: NCT05003986·Phase 2·Recruiting

Apply to this trial

RAPA-201 Therapy of Solid Tumors

for Solid Tumor

1 location in Hackensack

Sponsor: Rapa Therapeutics LLC

Sex: All·Age: 18+

Code: NCT05144698·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

149 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting

Apply to this trial

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

for Peripheral Vascular Diseases

52 locations incl. Jonesboro

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT04674969·Recruiting

Apply to this trial

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

for Medulloblastoma

23 locations incl. Little Rock

Sponsor: Giselle Sholler

Sex: All·Age: Up to 21

Code: NCT04696029·Phase 2·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol

for Severe Sepsis

10 locations incl. Irvine

Sponsor: Beckman Coulter, Inc.

Sex: All·Age: 18 - 89

Code: NCT05304728·Enrolling By Invitation

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

Drug: Nivolumab

202 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting

Apply to this trial

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

for Sickle Cell Disease

15 locations incl. Birmingham

Sponsor: Genetix Biotherapeutics Inc.

Sex: All·Age: 2 - 53

Code: NCT04628585·Enrolling By Invitation

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

for Anaplastic Kidney Wilms Tumor

177 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT04322318·Phase 2·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

for Neuroblastoma

25 locations incl. Birmingham

Sponsor: Giselle Sholler

Sex: All·Age: Up to 31

Code: NCT04301843·Phase 2·Recruiting

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

185 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting

Apply to this trial

ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes

for Embryonal Tumor With Multilayered Rosettes

1 location in Hackensack

Sponsor: Hackensack Meridian Health

Sex: All·Age: All ages

Code: NCT04794686·Recruiting

Apply to this trial

HEALEY ALS Platform Trial - Master Protocol

for Amyotrophic Lateral Sclerosis

81 locations incl. Phoenix

Sponsor: Merit E. Cudkowicz, MD

Sex: All·Age: 18+

Code: NCT04297683·Phase 2, Phase 3·Recruiting

Apply to this trial

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

for Intracerebral Hemorrhage

187 locations incl. Birmingham

Sponsor: Yale University

Sex: All·Age: 18+

Code: NCT03907046·Phase 3·Recruiting

Apply to this trial

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia

Drug: Revumenib

22 locations incl. Duarte

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 30 Days+

Code: NCT04065399·Phase 1, Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for Advanced Solid Tumor

Drug: Tulmimetostat

17 locations incl. Atlanta

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04104776·Phase 1, Phase 2·Recruiting

Apply to this trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for Castration Levels of Testosterone

334 locations incl. Gilbert

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT03678025·Phase 3·Recruiting

Apply to this trial

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

for B-cell Acute Lymphoblastic Leukemia

24 locations incl. Birmingham

Sponsor: Pediatric Transplantation & Cellular Therapy Consortium

Sex: All·Age: 1 - 25

Code: NCT03509961·Phase 2·Recruiting

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

100 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Drug: Mevrometostat

45 locations incl. Tucson

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT03460977·Phase 1·Recruiting

Apply to this trial